ロード中...

Pertuzumab and trastuzumab: the rationale way to synergy

It has now been 15 years since the HER2-targeted monoclonal antibody trastuzumab was introduced in clinical and revolutionized the treatment of HER2-positive breast cancer patients. Despite this achievement, most patients with HER2-positive metastatic breast cancer...

詳細記述

保存先:
書誌詳細
出版年:Anais da Academia Brasileira de Ciências
主要な著者: Sandrine Richard, Frédéric Selle, Jean-Pierre Lotz, Ahmed Khalil, Joseph Gligorov, Daniele G. Soares
フォーマット: Artigo
言語:Inglês
出版事項: Academia Brasileira de Ciências 2016
主題:
オンライン・アクセス:https://www.redalyc.org/articulo.oa?id=32746362012
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!